Scott Callaghan, DO
Neurology · Murrells Inlet, SCNPI 1497747018
Payments from drug & device makers
Across 284 payments — averaging $10.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$398
- Supernus Pharmaceuticals, Inc.$374
- UCB, Inc.$205
- Teva Pharmaceuticals USA, Inc.$166
- Sunovion Pharmaceuticals Inc.$131
- EMD Serono, Inc.$114
- plus $2K from 35 others
What the payments were for
- Speaking & faculty fees$632%
- Food & beverage$2,82597%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $398 |
| Supernus Pharmaceuticals, Inc. | 120 | $374 |
| UCB, Inc. | 10 | $205 |
| Teva Pharmaceuticals USA, Inc. | 11 | $166 |
| Sunovion Pharmaceuticals Inc. | 11 | $131 |
| EMD Serono, Inc. | 8 | $114 |
| Lilly USA, LLC | 6 | $112 |
| Avanir Pharmaceuticals, Inc. | 6 | $104 |
| Adamas Pharmaceuticals, Inc. | 6 | $95 |
| Upsher-smith Laboratories LLC | 5 | $89 |
| Sanofi | 5 | $87 |
| Novartis | 4 | $79 |
| TG Therapeutics, Inc. | 4 | $78 |
| Jazz Pharmaceuticals Inc. | 4 | $70 |
| Amgen | 4 | $63 |
| Acorda Therapeutics, Inc | 4 | $63 |
| Biogen | 3 | $58 |
| ANI Pharmaceuticals, Inc. | 2 | $51 |
| Pfizer | 3 | $47 |
| Johnson & Johnson | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| CSL Behring | 2 | $44 |
| Genentech USA, Inc. | 3 | $35 |
| Acadia Pharmaceuticals Inc | 2 | $35 |
| Boston Scientific | 2 | $33 |
| AstraZeneca | 2 | $30 |
| Eisai Inc. | 2 | $28 |
| Kyowa Kirin, Inc. | 2 | $28 |
| Tanabe Pharma America, Inc. | 2 | $27 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
| Greenwich Biosciences, Inc. | 1 | $19 |
| Abbott | 1 | $16 |
| Medtronic | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| Merck | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
| Travere Therapeutics, Inc. | 4 | $7 |
How this compares
$2,908 in reported general payments places this provider in the 60th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 13 | $548,268 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 12 | $213,996 |
| AustedoDeutetrabenazine | 18 | $112,738 |
| Nurtec OdtRimegepant Sulfate | 42 | $68,910 |
| NuplazidPimavanserin Tartrate | 11 | $46,009 |
| Aimovig AutoinjectorErenumab-Aooe | 43 | $42,330 |
| Rivastigmine | 133 | $21,903 |
| Emgality PenGalcanezumab-Gnlm | 26 | $20,702 |
| QuliptaAtogepant | 17 | $20,695 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 18 | $12,668 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 259 | $10,091 |
| Primidone | 218 | $9,311 |
| Donepezil Hcl | 756 | $8,476 |
| Oxcarbazepine | 83 | $8,194 |
| Levetiracetam | 236 | $7,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Catalyst Pharmaceuticals, Inc.Firdapse | $21 | $548,26813 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $166 | $112,73818 claims |
| PfizerNurtec Odt | $47 | $68,91042 claims |
| Acadia Pharmaceuticals IncNuplazid | $35 | $46,00911 claims |
| AbbVieQulipta | $398 | $20,69517 claims |
| Upsher-smith Laboratories LLCTopiramate | $89 | $2,035160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 270 neurology providers in South Carolina.
Other neurology in Murrells Inlet
- Michael McCaffreyMurrells Inlet$36K
- Mary HughesGreenville$6.3M
- William McElveenColumbia$3.7M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
- Paul MazzeoPort Royal$1.7M
- Vanessa HinsonCharleston$1.5M
- David SticklerNorth Charleston$1.2M
- Katherine RuzhanskyCharleston$1.1M
- Nicholas MilanoCharleston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.